Pilot randomized phase II study of celecoxib in oral premalignant lesions Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Mouth Neoplasms
  • Precancerous Conditions
  • Pyrazoles
  • Sulfonamides

abstract

  • Celecoxib at 100 or 200 mg twice daily was ineffective in controlling OPLs in this randomized controlled trial. This result and cardiovascular toxicity results of other (large scale) randomized controlled trials of selective COX-2 inhibitors have discouraged the continued investigation of these agents in oral cancer chemoprevention. Better methods for identifying high-risk patients and more active interventions are needed for future oral cancer chemoprevention trials.

publication date

  • April 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-4024

PubMed ID

  • 18381950

Additional Document Info

start page

  • 2095

end page

  • 101

volume

  • 14

number

  • 7